TVTX

Travere Therapeutics, Inc.

Name: Travere Therapeutics, Inc. insider trading (SEC Form 4) history
Creator: U.S. Securities and Exchange Commission

SEC CIK 1438533

$52.04 +64.3% · 90 days

90-day buys

0 open-market

90-day sells

$7.82M

21 open-market

Net insider flow

−$7.82M

Net selling

Filings shown

Most recent

At a glance

Over the last 90 days, insiders at TVTX have sold a net $7.82M of stock (0 open-market buys vs 21 sells).

Largest recent trade: Baynes Roy D. sold $1.07M of TVTX, trimming their stake 37%.

Most active filer: Heerma Peter, with 28 transactions among the recent filings shown.

Insider transaction history

Form 4 filings for TVTX, newest first

View on SEC EDGAR ↗

TVTX

Travere Therapeutics, Inc.

Option exercise Heerma Peter · CHIEF COMMERCIAL OFFICER · Option exercise · filed May 6, 2026 ΔOwn +3.1%

+$0

4,250 sh

TVTX

Travere Therapeutics, Inc.

Option exercise Dube Eric M · Director, CHIEF EXECUTIVE OFFICER · Option exercise · filed May 6, 2026 ΔOwn +5.2%

+$0

22,500 sh

TVTX

Travere Therapeutics, Inc.

Option exercise Cline Christopher R. · CHIEF FINANCIAL OFFICER · Option exercise · filed May 6, 2026 ΔOwn +3.6%

+$0

4,250 sh

TVTX

Travere Therapeutics, Inc.

Option exercise Baynes Roy D. · Director · Option exercise · filed May 4, 2026 ΔOwn +26%

+$66.5K

9,750 sh @ $7

TVTX

Travere Therapeutics, Inc.

Sell Baynes Roy D. · Director · Open-market sale · filed May 4, 2026 ΔOwn −21%

Baynes Roy D. sold $431.1K of TVTX, trimming their stake 21%.

−$431.1K

9,750 sh @ $44

TVTX

Travere Therapeutics, Inc.

Sell ROTE WILLIAM E. · Chief Research Officer · Open-market sale · filed Apr 23, 2026 ΔOwn −7.4%

Rote William E. sold $355.7K of TVTX, trimming their stake 7%.

−$355.7K

9,100 sh @ $39

TVTX

Travere Therapeutics, Inc.

Option exercise LYONS GARY A · Director · Option exercise · filed Apr 16, 2026 ΔOwn +14%

+$130.6K

8,000 sh @ $16

TVTX

Travere Therapeutics, Inc.

Sell LYONS GARY A · Director · Open-market sale · filed Apr 16, 2026 ΔOwn −12%

Lyons Gary A sold $328.6K of TVTX, trimming their stake 12%.

−$328.6K

8,000 sh @ $41

TVTX

Travere Therapeutics, Inc.

Option exercise Baynes Roy D. · Director · Option exercise · filed Apr 16, 2026 ΔOwn +21%

+$143.5K

8,000 sh @ $18

TVTX

Travere Therapeutics, Inc.

Option exercise Baynes Roy D. · Director · Option exercise · filed Apr 16, 2026 ΔOwn +20%

+$138.9K

9,000 sh @ $15

TVTX

Travere Therapeutics, Inc.

Option exercise Baynes Roy D. · Director · Option exercise · filed Apr 16, 2026 ΔOwn +8.3%

+$82.2K

4,500 sh @ $18

TVTX

Travere Therapeutics, Inc.

Option exercise Baynes Roy D. · Director · Option exercise · filed Apr 16, 2026 ΔOwn +7.6%

+$96.2K

4,500 sh @ $21

TVTX

Travere Therapeutics, Inc.

Option exercise Baynes Roy D. · Director · Option exercise · filed Apr 16, 2026 ΔOwn +11%

+$115.5K

6,750 sh @ $17

TVTX

Travere Therapeutics, Inc.

Sell Baynes Roy D. · Director · Open-market sale · filed Apr 16, 2026 ΔOwn −37%

Baynes Roy D. sold $1.07M of TVTX, trimming their stake 37%.

−$1.07M

26,000 sh @ $41

TVTX

Travere Therapeutics, Inc.

Sell Baynes Roy D. · Director · Open-market sale · filed Apr 16, 2026 ΔOwn −15%

Baynes Roy D. sold $284.3K of TVTX, trimming their stake 15%.

−$284.3K

6,750 sh @ $42

TVTX

Travere Therapeutics, Inc.

Option exercise Calvin Sandra · SVP, CHIEF ACCOUNTING OFFICER · Option exercise · filed Apr 16, 2026 ΔOwn +5.1%

+$56K

2,500 sh @ $22

TVTX

Travere Therapeutics, Inc.

Option exercise Calvin Sandra · SVP, CHIEF ACCOUNTING OFFICER · Option exercise · filed Apr 16, 2026 ΔOwn +12%

+$55.8K

6,250 sh @ $9

TVTX

Travere Therapeutics, Inc.

Option exercise Calvin Sandra · SVP, CHIEF ACCOUNTING OFFICER · Option exercise · filed Apr 16, 2026 ΔOwn +11%

+$133K

6,500 sh @ $20

TVTX

Travere Therapeutics, Inc.

Sell Calvin Sandra · SVP, CHIEF ACCOUNTING OFFICER · Open-market sale · filed Apr 16, 2026 ΔOwn −34%

Calvin Sandra sold $902.6K of TVTX, trimming their stake 34%.

−$902.6K

21,977 sh @ $41

TVTX

Travere Therapeutics, Inc.

Sell Heerma Peter · CHIEF COMMERCIAL OFFICER · Open-market sale · filed Apr 15, 2026 ΔOwn −4.9%

Heerma Peter sold $302.5K of TVTX, trimming their stake 5%.

−$302.5K

7,215 sh @ $42

TVTX

Travere Therapeutics, Inc.

Grant/award Heerma Peter · CHIEF COMMERCIAL OFFICER · Grant/award · filed Apr 15, 2026 ΔOwn +11%

+$0

14,000 sh

TVTX

Travere Therapeutics, Inc.

Grant/award ROTE WILLIAM E. · Chief Research Officer · Grant/award · filed Apr 15, 2026 ΔOwn +13%

+$0

14,000 sh

TVTX

Travere Therapeutics, Inc.

Sell Heerma Peter · CHIEF COMMERCIAL OFFICER · Open-market sale · filed Feb 3, 2026 ΔOwn −5.3%

Heerma Peter sold $234.8K of TVTX, trimming their stake 5%.

−$234.8K

7,310 sh @ $32

TVTX

Travere Therapeutics, Inc.

Sell Heerma Peter · CHIEF COMMERCIAL OFFICER · Open-market sale · filed Dec 29, 2025 ΔOwn −4.2%

Heerma Peter sold $199.2K of TVTX, trimming their stake 4%.

−$199.2K

4,980 sh @ $40

TVTX

Travere Therapeutics, Inc.

Sell Coughlin Timothy · Director · Open-market sale · filed Nov 4, 2025 ΔOwn −24%

Coughlin Timothy sold $630.6K of TVTX, trimming their stake 24%.

−$630.6K

18,000 sh @ $35

TVTX

Travere Therapeutics, Inc.

Sell Heerma Peter · CHIEF COMMERCIAL OFFICER · Open-market sale · filed Nov 4, 2025 ΔOwn −4.5%

Heerma Peter sold $195.7K of TVTX, trimming their stake 4%.

−$195.7K

5,591 sh @ $35

TVTX

Travere Therapeutics, Inc.

Sell Heerma Peter · CHIEF COMMERCIAL OFFICER · Open-market sale · filed Oct 30, 2025 ΔOwn −2.1%

Heerma Peter sold $79.9K of TVTX, trimming their stake 2%.

−$79.9K

2,662 sh @ $30

TVTX

Travere Therapeutics, Inc.

Sell Heerma Peter · CHIEF COMMERCIAL OFFICER · Open-market sale · filed May 5, 2025 ΔOwn −1.4%

Heerma Peter sold $37.3K of TVTX, trimming their stake 1%.

−$37.3K

1,771 sh @ $21

TVTX

Travere Therapeutics, Inc.

Sell Heerma Peter · CHIEF COMMERCIAL OFFICER · Open-market sale · filed Feb 12, 2025 ΔOwn −2.0%

Heerma Peter sold $60.4K of TVTX, trimming their stake 2%.

−$60.4K

2,568 sh @ $24

TVTX

Travere Therapeutics, Inc.

Sell Heerma Peter · CHIEF COMMERCIAL OFFICER · Open-market sale · filed Feb 12, 2025 ΔOwn −2.4%

Heerma Peter sold $76.9K of TVTX, trimming their stake 2%.

−$76.9K

3,074 sh @ $25

About TVTX insider activity

This page tracks every recent Form 4 filed for Travere Therapeutics, Inc. with the U.S. Securities and Exchange Commission. Form 4 is the disclosure that company insiders — officers, directors, and holders of more than 10% of the stock — must file within two business days of buying or selling shares.

The summary above nets open-market purchases against open-market sales over the trailing 90 days. Open-market trades (codes P and S) tend to carry the most signal because they reflect a deliberate choice to put money in or take it out, as opposed to routine grants, option exercises, or tax-withholding events. Use the badges on each row to tell them apart, and always confirm details against the original filing before drawing conclusions.

Frequently asked questions

How often is TVTX insider data updated?

Continuously. We read from SEC EDGAR, so new Form 4 filings for Travere Therapeutics, Inc. usually appear here within minutes of being accepted by the SEC.

What does "net insider flow" mean?

It is the total dollar value of open-market insider purchases minus open-market sales over the last 90 days. A positive number (green) means insiders bought more than they sold; a negative number (red) means the reverse.

Why do some rows show grants or option exercises instead of buys?

Insiders receive stock through compensation as well as buying it outright. Form 4 captures all of these. We label each transaction by its SEC code so you can focus on open-market activity if you prefer.

Is this investment advice?

No. InsiderSource presents public filing data for informational purposes only. Insider activity is one of many factors to consider and is never a recommendation to buy or sell.